ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 02 Jan 2024
Last Updated on 02 Jan 2024
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended ferric derisomaltose for inclusion on the MOH List of Subsidised Drugs for treating iron deficiency anaemia due to unfavourable cost-effectiveness compared with ferric carboxymaltose at the price proposed by the manufacturer.

Ferric derisomaltose for treating iron deficiency anemia (Published 2 Jan 2024)